Safety and efficacy of Tenofovir/Emtricitabine or Abacavir/Lamivudine in combination with Efavirenz in Treatment Naïve HIV patients: A 5 year retrospective observational cohort study. (The TOKEN Study)

2013 ◽  
Vol 67 (9) ◽  
pp. 922-923 ◽  
Author(s):  
M. Pammi ◽  
J. Arumainayagam ◽  
B. Kumari ◽  
I. Ahmed-Jushuf ◽  
E. M Carlin ◽  
...  
2019 ◽  
Author(s):  
Fang Liu ◽  
Aifang Xu ◽  
Huaqing Zhao ◽  
Zongxing Yang ◽  
Chen Chen ◽  
...  

Abstract Background Estimated glomerular filtration rate (eGFR) trajectory in HIV-1-infected patients on tenofovir disoproxil fumarate (TDF) – based therapy has been widely assessed using linear models, but this linearity assumption is disputable and the nonlinearity of eGFR change remains unknown in patients with initially normal renal function. Methods This is a retrospective, observational cohort study in treatment-naïve HIV-1-infected patients in Hangzhou, China. Estimated GFR (calculated by MDRD equation) trajectories were compared by one-linear and piecewise-linear mixed effects models, before and after propensity matching, respectively. Whether the incidence of renal dysfunction (reduced renal function [RRF], eGFR < 90 mL/min/1.73 m² and rapid kidney function decline [RKFD], eGFR > -3 mL/min/1.73 m² /year) follows nonlinearity was assessed by logistic regression. Results We examined 823 (299 of TDF users and 524 of non-TDF users) treatment-naïve HIV-1-infected participants (age≥17 years) with initial eGFR greater than 90 mL/min/1.73m² . The median follow-up time was 10 (interquartile range, 2-20) months, during which 178 (21.6%) experienced RRF, and 451 (54.8%) experienced RKFD. In nonlinear adjusted model, the eGFR of TDF users decreased over time before 1.40 years (-5.31 mL/min/1.73 m² /year; 95% CI: -6.57, -4.06), and after 2.30 years (-3.71 mL/min/1.73 m² /year; 95% CI: -5.97, -1.45). However, the eGFR significantly improved from years 1.40 to 2.30 (4.83 mL/min/1.73 m² /year; 95% CI: 1.38, 8.28). Within this particular time frame, each year of TDF exposure was associated with a 78% decreased risk of RKFD (95% CI: -91%, -49%). In comparison, eGFR increased slightly at the initiation of antiviral therapy, declined after 2.15 years (-4.96 mL/min/1.73 m² /year; 95% CI: -5.76, -4.17) among non-TDF users. Such a progression nonlinear trajectory was missed on the assumption of one-linearity, whether in TDF or non-TDF users. Conclusion For HIV-1-infected Chinese initiated antiviral therapy with normal renal function, the nonlinear trajectory of renal function do exist, as revealed by the piecewise mixed effects model with advantage of speaking to the true nature of the exposure outcome relationships. Routine screen based on this nonlinear progression of eGFR, could be helpful for patient management.


2020 ◽  
Vol 0 (0) ◽  
Author(s):  
Sunil Jaiman ◽  
Roberto Romero ◽  
Percy Pacora ◽  
Eunjung Jung ◽  
Gaurav Bhatti ◽  
...  

Abstract Objective The aims of this study were to ascertain the frequency of disorders of villous maturation in fetal death and to also delineate other placental histopathologic lesions in fetal death. Methods This was a retrospective observational cohort study of fetal deaths occurring among women between January 2004 and January 2016 at Hutzel Women’s Hospital, Detroit, MI, USA. Cases comprised fetuses with death beyond 20 weeks’ gestation. Fetal deaths with congenital anomalies and multiple gestations were excluded. Controls included pregnant women without medical/obstetrical complications and delivered singleton, term (37–42 weeks) neonate with 5-min Apgar score ≥7 and birthweight between the 10th and 90th percentiles. Results Ninety-two percent (132/143) of placentas with fetal death showed placental histologic lesions. Fetal deaths were associated with (1) higher frequency of disorders of villous maturation [44.0% (64/143) vs. 1.0% (4/405), P < 0.0001, prevalence ratio, 44.6; delayed villous maturation, 22% (31/143); accelerated villous maturation, 20% (28/143); and maturation arrest, 4% (5/143)]; (2) higher frequency of maternal vascular malperfusion lesions [75.5% (108/143) vs. 35.7% (337/944), P < 0.0001, prevalence ratio, 2.1] and fetal vascular malperfusion lesions [88.1% (126/143) vs. 19.7% (186/944), P < 0.0001, prevalence ratio, 4.5]; (3) higher frequency of placental histologic patterns suggestive of hypoxia [59.0% (85/143) vs. 9.3% (82/942), P < 0.0001, prevalence ratio, 6.8]; and (4) higher frequency of chronic inflammatory lesions [53.1% (76/143) vs. 29.9% (282/944), P < 0.001, prevalence ratio 1.8]. Conclusion This study demonstrates that placentas of womem with fetal death were 44 times more likely to present disorders of villous maturation compared to placentas of those with normal pregnancy. This suggests that the burden of placental disorders of villous maturation lesions is substantial.


Sign in / Sign up

Export Citation Format

Share Document